Bristol-myers Squibb

This study tested an experimental drug called MORAb-202 in people with a specific type of advanced lung cancer that had spread and worsened despite prior treatments. The goal was to see if the drug was safe and if it could shrink tumors. The trial was stopped early and only enrol…

This early-stage study aimed to find a safe dose and check for side effects of an experimental drug called CC-95251. It was tested alone and combined with other cancer drugs in 56 adults with advanced or returning forms of acute myeloid leukemia (AML) and myelodysplastic syndrome…

This study tested whether a two-drug immunotherapy combination works better than a single drug to prevent melanoma from returning after it has been surgically removed. It involved over 1,000 patients whose stage III or IV melanoma was completely cut out. The goal was to see which…

This study aimed to see if adding an immunotherapy drug called nivolumab to the standard BCG treatment could better control high-risk bladder cancer that had come back or persisted after initial BCG therapy. It was a large Phase 3 trial that was terminated early, enrolling only 1…

This early-stage study aimed to find a safe dose for a new experimental drug called BMS-986258, testing it alone and combined with an existing immunotherapy (nivolumab) in people with advanced cancers. It enrolled 92 participants with specific advanced tumors who had already trie…

This study aimed to learn more about how the approved drug ozanimod works for people with moderate to severe ulcerative colitis in everyday medical practice. It involved 139 participants and looked at how well the drug controlled their symptoms, its safety, and how it affected th…

This early-stage study aimed to understand how moderate or severe liver problems affect the way a cancer drug (oral azacitidine) is processed in the body. It planned to compare adults with blood cancers and liver impairment to those with normal liver function. The main goal was t…